AR066885A1 - Proteinas de fusion natriureticas - Google Patents

Proteinas de fusion natriureticas

Info

Publication number
AR066885A1
AR066885A1 ARP080102404A ARP080102404A AR066885A1 AR 066885 A1 AR066885 A1 AR 066885A1 AR P080102404 A ARP080102404 A AR P080102404A AR P080102404 A ARP080102404 A AR P080102404A AR 066885 A1 AR066885 A1 AR 066885A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
disclosed
natural fusion
compose
linker
Prior art date
Application number
ARP080102404A
Other languages
English (en)
Inventor
Keith Canada
Uwe Schoenbeck
Adam Mezo
Kevin Mcdonnell
Eugene R Hickey
Original Assignee
Boehringer Ingelheim Int
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066885(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Syntonix Pharmaceuticals Inc filed Critical Boehringer Ingelheim Int
Publication of AR066885A1 publication Critical patent/AR066885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

Se dan a conocer proteínas de fusion de péptido natriurético que comprenden péptidos natriuréticos unidos a dominios Fc de anticuerpo a través de un conector (compue por aminoácidos) moléculas de ácido nucleico que codifican para las proteínas de fusion dadas a conocer en el presente documento, vectores de expresion que expresan dichas proteínas de fusion, composiciones farmacéuticas que comprenden dichas proteínas de fusion y métodos para su uso terapéutico.
ARP080102404A 2007-06-06 2008-06-05 Proteinas de fusion natriureticas AR066885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94245507P 2007-06-06 2007-06-06

Publications (1)

Publication Number Publication Date
AR066885A1 true AR066885A1 (es) 2009-09-16

Family

ID=39717543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102404A AR066885A1 (es) 2007-06-06 2008-06-05 Proteinas de fusion natriureticas

Country Status (10)

Country Link
US (1) US20100310561A1 (es)
EP (1) EP2162464A1 (es)
JP (1) JP2010530222A (es)
AR (1) AR066885A1 (es)
CA (1) CA2689492A1 (es)
CL (1) CL2008001661A1 (es)
PE (1) PE20090311A1 (es)
TW (1) TW200906849A (es)
UY (1) UY31123A1 (es)
WO (1) WO2008154226A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3404102T1 (sl) 2004-04-21 2021-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
DK3175863T3 (da) 2009-05-20 2022-02-07 Biomarin Pharm Inc Varianter af c-type natriuretisk peptid
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
CN103153344A (zh) 2010-04-30 2013-06-12 阿莱克森国际制药有限公司 用于治疗基质矿化障碍的方法、组合物、和试剂盒
US8921516B2 (en) * 2010-12-08 2014-12-30 Corning Incorporated Synthetic, defined fibronectin mimetic peptides and surfaces modified with the same
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
KR101969526B1 (ko) 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 악성 종양 전이 억제용 의약
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
SI3701971T1 (sl) * 2014-03-14 2023-01-31 Biomolecular Holdings LLC, Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN104861075B (zh) * 2015-05-08 2018-06-08 成都金凯生物技术有限公司 一种长效重组人脑钠肽融合蛋白及其制备方法与用途
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
RU2754558C2 (ru) 2016-04-01 2021-09-03 Алексион Фармасьютикалз, Инк. Лечение мышечной слабости с помощью щелочных фосфатаз
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11008392B2 (en) 2016-07-01 2021-05-18 Daiichi Sankyo Company, Limited HANP-Fc-containing molecular conjugate
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CA3056433A1 (en) * 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
AU2019368196A1 (en) * 2018-10-23 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-NPR1 antibodies and uses thereof
CN110964098B (zh) * 2019-10-23 2022-10-04 武汉奥科博泰生物科技有限公司 一种n端脑钠肽变体蛋白及其制备方法和应用
WO2024086680A2 (en) 2022-10-21 2024-04-25 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
AU2004257142A1 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
ES2372495T3 (es) * 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
JP2009511060A (ja) * 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質
US8008257B2 (en) * 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region

Also Published As

Publication number Publication date
UY31123A1 (es) 2008-11-28
WO2008154226A1 (en) 2008-12-18
CA2689492A1 (en) 2008-12-18
JP2010530222A (ja) 2010-09-09
US20100310561A1 (en) 2010-12-09
CL2008001661A1 (es) 2009-03-20
EP2162464A1 (en) 2010-03-17
PE20090311A1 (es) 2009-04-09
TW200906849A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
AR066885A1 (es) Proteinas de fusion natriureticas
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
HRP20200007T1 (hr) Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
IL261432B1 (en) Induced binding proteins and methods of use
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
AR062030A1 (es) Proteinas de fusion de exendina
AR077088A1 (es) Proteinas biespecificas de union a antigeno
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
RU2020106752A (ru) Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
EA201490262A1 (ru) Модифицированные белки и пептиды
BRPI0811333B8 (pt) proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
ATE480568T1 (de) Verbesserte sgp 130fc dimere
NO20092697L (no) Transportmolekyler ved bruk av revers-sekvens HIV-TAT polypeptider

Legal Events

Date Code Title Description
FA Abandonment or withdrawal